In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|January 14, 2020
BrevisRefero Launches Online RFP Platform
Author(s)BioPharm International Editors
The new automated service connects companies with biologics development and manufacturing services.
Advertisement
BrevisRefero, a platform for managing Request for Proposals (RFP), announced on Jan. 8, 2020 that it launched an online platform for biotech companies and service providers. The new service provides companies with biologics development and manufacturing services at a lower cost and with faster results, the company said in a press release.
During its beta-launch, the platform successfully helped businesses deliver their RFPs to service providers within days, rather than the weeks required for a typical RFP manual process, the press release said. The company also offers a concierge member support service staffed with outsourcing professionals to help companies through the online process.
“We started BrevisRefero to be more than just a place to post RFPs. BrevisRefero assists pharma and biotech companies in finding optimal contract development and manufacturing organizations (CDMOs) faster and in a more data-driven way based on our 20 plus years of experience in the biotech industry,'' said Terry Cochrane, founder and president of BrevisRefero, in the press release. “Our secure online platform provides instant access to a global network of service providers, a simplified confidentiality process, consistent RFP formats, and powerful analytical tools that allow direct side by side comparisons of proposals so innovators can make the best outsourcing decisions faster than ever.”
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5